Concentration- and region-dependent intestinal permeability of fluvastatin in the rat

被引:26
作者
Lindahl, A
Sandström, R
Ungell, AL
Lennernäs, H
机构
[1] Univ Uppsala, Ctr Biomed, Dept Pharm, S-75123 Uppsala, Sweden
[2] AB Hassle, Pharmaceut R&D, Drug Delivery Res, S-43183 Molndal, Sweden
关键词
D O I
10.1111/j.2042-7158.1998.tb07134.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to investigate the mechanisms of transport of fluvastatin across the intestinal mucosa in various regions of the intestine in the rat. In-situ single-pass perfusions of the jejunum, ileum and colon were performed and the effective permeability (P-eff) of fluvastatin, antipyrine and D-glucose were assessed in each region, at three different perfusate fluvastatin concentrations (1.6, 16 and 160 mu M). The effect of lovastatin acid on the bi-directional transport of fluvastatin across the ileal mucosa was also studied. The P-eff of fluvastatin was found to be dependent both on the intestinal region and on the concentration in the intestinal lumen (P<0.001). Fluvastatin had the lowest P-eff (0.55 +/- 0.10 x 10(-4) cm s(-1)) in the jejunum at 1.6 mu M, and the highest P-eff (1.0 +/- 0.16 x 10(-4) cm s(-1)) in the colon at 160 mu M. The highest concentration of fluvastatin increased the average absorption of water from the intestine by 209% (P < 0.05), and the average P-eff of D-glucose by 29% (P < 0.05). The presence of excess lovastatin acid (100 mu M, compared with fluvastatin 1.6 mu M) at the luminal side increased the average absorption of water by 218% (P < 0.001), and the P-eff of fluvastatin in the ileum and the colon by 44 and 50%, respectively (P < 0.05). The presence of lovastatin acid on the luminal side in the ileum also increased the blood-to-lumen transport (exsorption) of fluvastatin by 43% (P < 0.001). The increased intestinal absorption of fluvastatin at higher concentrations does not suggest that substantial absorption occurs by any carrier-mediated process in the absorptive direction. The increased bi-directional transport when lovastatin acid was added to the lumen suggests that fluvastatin is not a P-glycoprotein substrate. Instead, the concentration-dependent increase in the absorption of fluvastatin, water and D-glucose suggests a direct effect of fluvastatin on the transcellular passive transport.
引用
收藏
页码:737 / 744
页数:8
相关论文
共 28 条
[1]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[2]   EPITHELIAL TRANSPORT OF DRUGS IN CELL-CULTURE .7. EFFECTS OF PHARMACEUTICAL SURFACTANT EXCIPIENTS AND BILE-ACIDS ON TRANSEPITHELIAL PERMEABILITY IN MONOLAYERS OF HUMAN INTESTINAL EPITHELIAL (CACO-2) CELLS [J].
ANDERBERG, EK ;
NYSTROM, C ;
ARTURSSON, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (09) :879-887
[3]  
CHADWICK VS, 1977, GASTROENTEROLOGY, V73, P247
[4]   HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein-expressing cells [J].
Dimitroulakos, J ;
Yeger, H .
NATURE MEDICINE, 1996, 2 (03) :326-333
[5]   Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms [J].
Fagerholm, U ;
Lindahl, A ;
Lennernas, H .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 (07) :687-690
[6]   Comparison between permeability coefficients in rat and human jejunum [J].
Fagerholm, U ;
Johansson, M ;
Lennernas, H .
PHARMACEUTICAL RESEARCH, 1996, 13 (09) :1336-1342
[7]  
FAGERHOLM U, 1997, THESIS UPPSALA U SWE
[8]   PERMEABILITY CHARACTERISTICS OF VARIOUS INTESTINAL REGIONS OF RABBIT, DOG, AND MONKEY [J].
JEZYK, N ;
RUBAS, W ;
GRASS, GM .
PHARMACEUTICAL RESEARCH, 1992, 9 (12) :1580-1586
[9]  
KEYOMARSI K, 1991, CANCER RES, V51, P3602
[10]   QUANTITATIVE MECHANISTIC STUDIES IN SIMULTANEOUS FLUID-FLOW AND INTESTINAL-ABSORPTION USING STEROIDS AS MODEL SOLUTES [J].
KOMIYA, I ;
PARK, JY ;
KAMANI, A ;
HO, NFH ;
HIGUCHI, WI .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1980, 4 (03) :249-262